ExpectedOutcome:
EIC Transition aims at maturing both your technology and business idea thus increasing its technology and market readiness. The expected outcomes of an EIC Transition project are a) a technology that is demonstrated to be effective for its intended application and b) a business model, its initial validation and a business plan for its development to market. It is also expected that the intellectual property generated by the EIC Transition project is formally protected in an adequate way.
For more details, see the WP 2022.
Objective:Proposals submitted to this EIC Transition Challenge call should focus on one or more of the following specific objectives:
EIC Transition funds innovation activities that go beyond the experimental proof of principle in laboratory. It supports both the maturation and validation of a novel technology from the lab to the relevant application environments (by making use of prototyping, formulation, models, user testing or other validation tests) as well as explorations and development of a sustainable business case and business model towards commercialisation.
Expected Impact:The starting point in the project should be a preliminary technology or protocol of an RNA-based therapy for complex or rare genetic diseases with unmet medical needs that demonstrates, in a lab or preclinical context, the essential features that underpin the disruptive nature of the innovation (TRL 3-4). The endpoint in the project should be a completely functional version of the technology suitable for clinical validation (TRL5-6), supported by a sound and implementable commercialisation/exploitation strategy.
Proposals are expected to contribute to at least one of the following outcomes: